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Abstract
Alzheimer’s disease is a neurodegenerative disease with no early diagnosis. 
Neuronal dysfunction is an early indication of Alzheimer’s disease which we can measure 
by examining the lysosomal protein Cathepsin-D. Molecular imaging of Cathepsin-D 
using Magnetic Resonance Imaging (MRI) contrast agents could enhance visualization of 
disease and provide contrast within tissues and cells that are morphologically similar but 
physiologically distinct. The purpose of our work was to evaluate a novel 
MRI/fluorescent contrast agent designed to detect Cathepsin-D in early Alzheimer’s 
disease.
In-vitro MRI and fluorescent sensitivity were characterized in addition to cellular 
uptake in cells over-expressing Cathepsin-D. Cortical and hippocampal uptake was 
evaluated following in-vivo injection of contrast agent in mice. The contrast agent 
exhibited differences in retention and uptake between control and transgenic Alzheimer’s 
mice. The results demonstrate the potential utility of the contrast agent for in-vivo 
identification of cathepsin-D upregulation and will continue to be further evaluated and 
refined in future studies.
Key Words: Alzheimer’s Disease, contrast agent, cathepsin-D, magnetic resonance 
imaging, cell-penetrating peptide, live cell imaging
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The work in this thesis is focused on Magnetic Resonance Imaging (MRI) and 
fluorescence imaging to study contrast agents designed to detect enzyme activity with an 
application to the diagnosis of early Alzheimer’s disease (AD). These imaging modalities 
were used to test and characterize the sensitivity and molecular behavior of newly 
developed contrast agents.
The following chapter provides an introduction to the physiological and cellular 
changes that occur in Alzheimer’s disease, a background on magnetic resonance and 
fluorescence imaging, and their application of these methods to brain imaging. 
Preliminary work performed on the synthesis, design, and testing of a dual 
MRI/fluorescent contrast agent is also presented from a manuscript published in Organic 
and Biomolecular Chemistry, entitled A Paramagnetic Chemical Exchange-Based MRI 
Probe Metabolized by Cathepsin-D: Design, Synthesis, and Cellular Uptake Studies.
1.2 Alzheimer’s Disease
Alzheimer’s disease is a neurodegenerative process that destroys neurons in the 
brain and ultimately leads to impaired cognitive function and death [1,2]. It was first 
described by Alois Alzheimer in 1906 when he observed deposits of plaques in the post 
mortem examination of a patient [3]. Alzheimer’s disease is the most common form of 
dementia, which is a group of symptoms found in other diseases such as vascular 
dementia, frontotemporal dementia, Creutzfeldt-Jakob disease, and Lewy-body dementia
[4].
2
1.2.1 Alzheimer’s Disease Pathology
Since Alois Alzheimer originally observed extracellular plaques and intracellular 
neurofibrillary tangles (NFTs), these have remained the gold-standard in diagnosing AD 
neuropathology [2], However, the exact biological mechanism of AD continues to 
remain a mystery. Over time, research has identified several key mechanistic theories to 
explain its initiation and progression, which are now dominated by the amyloid cascade 
hypothesis. Although plaques and NFTs are used as diagnostic criteria, it would be 
misleading to state that these are the only significant pathological changes occurring in 
the AD brain. In fact, numerous other structural and functional alterations ensue, 
including inflammatory responses and oxidative stress [5-8], The combined consequence 
of all these pathological changes, including the effects of the Ap and tau pathologies, is 
severe neuronal and synaptic dysfunction and loss. The National Institute of Aging- 
Alzheimer’s Association had recently refined the diagnosis of AD [9]. However, it still 
contains the original framework of diagnostic criteria outlined in 1984 with the addition 
of research knowledge including new biomarkers and imaging to increase the sensitivity 
of diagnosis.
The amyloid cascade hypothesis has been challenged as an accurate model of AD 
initiation and pathogenesis, particularly due to the discovery of significant Ap loads in 
non-demented individuals, the absence of such loads in demented individuals, and poor 
correlation between plaque clearance and that of rescued cognitive function [10]. Models 
placing inflammation and neurofibrillary tau tangles at the forefront of AD pathology 
have been offered as alternatives [10-12], The discrepancies outlined with the amyloid 
cascade hypothesis may be explained with a new theory that states pre-fibrillar, non- 
assembled P-amyloid is just as toxic as its assembled counterpart [13]. There have been
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an increasing number of these studies in the literature that support this theory through 
synthetic A(] peptides, cell culture models, P-amyloid precursor protein transgenic mice 
and human brain [14-16].
1.2.1.1 Lysosomal System
The remarkable abundance of undigested protein within accumulated autosomal 
vacuoles (AV), many of which contain lysosomal proteases, strongly implies a defect in 
the proteolytic clearance of autophagy substrates by lysosomes. In this regard, 
comparable levels of protein “storage” in the brain are most often observed in certain 
primary lysosomal storage diseases associated with severe cognitive disabilities and 
neurodegenerative phenotypes that share key neuropathological features of AD [17, 18]. 
Further implicating primary dysfunction of the lysosomal system in AD is evidence for a 
continuum of abnormalities within endocytic and autophagic pathways connected to 
lysosomes, some linked directly to genes causing early-onset AD [19-21], As a result, 
our work has been designed to seek out this lysosomal dysfunction in AD.
1.2.1.2 Cathepsin-D
Cathepsin-D (Cat-D) is a member of the aspartyl protease family found in all 
mammalian cells and normally localized to the lysosome [22, 23], Studies involving Cat- 
D have shown that it plays a role in several physiological functions including protein 
degradation, apoptosis, and autophagy [24], Cat-D is synthesized on the rough 
endoplasmic reticulum as a pre-pro-enzyme. This pre-pro-cathepsin-D contains an N- 
terminal secretion signal peptide that is removed during transport of the enzyme across 
the endoplasmic reticulum membrane. The result is an inactive pro-Cat-D enzyme with a
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size of 52 kDa. The pro-Cat-D enzyme is transported to the Golgi for further processing. 
The mannose-6-phosphate (M6P) pathway mediates the transport of pro-Cat-D to the 
lysosome from the golgi [25]. The M6P pathway helps to package the pro-Cat-D into 
vesicles to eventually deliver it to lysosomes. Once pro-Cat-D reaches lysosomal 
compartments, the low pH causes pro-Cat-D to be released from the M6P receptors and 
also the phosphate group is removed. The pro-peptide is then removed leaving Cat-D in 
an active intermediate form (48 kDa). The intermediate form is further cleaved by 
cathepsin B or L to form mature Cat-D consisting of a closely associated light chain (14 
kDa) and a carboxyl-terminal heavy chain (34 kDa) [26].
Cathepsin D (Cat-D) is over-expressed in several types of cancers and in 
Alzheimer’s disease, which makes it a potentially useful biomarker for these diseases. 
Specifically, Cat-D is upregulated in breast cancer [27], ovarian cancer [28], endometrial 
cancer [29], and prostate cancer [30], and has been associated with increased risk of 
metastasis [31]. Cat-D may be involved in processes of early tumour progression 
including the stimulation of cell proliferation, fibroblast outgrowth and angiogenesis [32], 
Therefore, the detection of over-expression of this protease may have prognostic value 
and help to identify subjects that require treatment, making it an excellent target as an 
imaging biomarker. With respect to Alzheimer’s disease (AD), a prevalent 
neurodegenerative brain disorder, it has been well documented that increased levels of 
lysosomal hydrolases in normal appearing neurons precede the earliest known 
histopathological features of AD [33], Over-expression, up to four times the normal 
expression of Cat-D [34-37], in Alzheimer’s disease patients also makes this protease a 
viable imaging biomarker for in-vivo AD detection since very early clinical diagnosis 
remains difficult [38],
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Polymorphisms in the Cat-D gene have also been loosely correlated with an 
increased risk for sporadic AD [39, 40] and Cat-D activity has been shown to increase 
early in AD [33]. Yet other studies alternately indicate a positive role for Cat-D in the 
degradation of toxic protein accumulations in-vivo, such as the alpha-synuclein, A[142, 
and tau aggregations which encompass the hallmark pathologies of Lewy Body and AD 
dementia [41]. Thus, while research has established Cat-D within a selection of AD- 
associated pathways, it remains unclear whether Cat-D plays an aggravating or restorative 
role in AD neuronal apoptosis.
1.2.2 Clinical Evaluation and Diagnosis of Alzheimer’s Disease
The early onset of Alzheimer’s disease typically occurs from before 60 years of 
age with chronic neurodegeneration until death at about six years following onset [42-44], 
The brain eventually displays significant atrophy; however, age-associated atrophy and 
the normal variability in brain size preclude a diagnosis based solely on gross 
examination of the brain [45], Large scale atrophy of the temporal lobe is often 
pronounced in comparison to other areas of the cortex. In most cases, the primary 
sensory and motor cortices are relatively spared and on sectioning the brain, the lateral 
ventricles are usually dilated and the hippocampus and amygdala are atrophic [45],
There are standardized cognitive and memory tests that neurologists include as 
tools to help aid in their diagnosis of Alzheimer’s disease. For example, the Mini-Mental 
State Exam (MMSE) is utilized by physicians to assess a patient’s memory, attention 
span, and problem solving skills [46]. The results provide insight into what areas of the 
brain may have been affected by the disease. These tests along with a clinical assessment 
and the process of elimination of other diseases provide physicians with up to 90% rate of
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success in diagnosing individuals with Alzheimer’s disease [47-49], Neurologists 
specializing in the dementias have the greatest accuracy while general practitioners have 
the lowest [45], This accuracy drops even further when these patients exhibit other kinds 
of related dementias [50], However, studies have also shown that the MMSE’s ability to 
predict or detect Alzheimer’s disease at an earlier stage declines in accuracy [51], Early 
detection and diagnosis is important so patients and their families understand what to 
expect and how to care for their family member. In addition, earlier diagnosis gives 
patients and their families time to discuss preventative measures such as lifestyle changes 
and to look after any future needs of the patient. Lastly, certain types of Alzheimer’s 
disease drugs may be most effective during the early onset of the disease before major 
cognitive deficits occur [52],
At the current time, the only definitive way to diagnose Alzheimer’s disease is 
with a post-mortem histological examination of the brain [2], Individuals with 
Alzheimer’s disease have an increased deposition of |3-amyloid plaques within the brain. 
Neurofibrillary tangles (tau protein) are also present at higher than normal quantities 
within the brain.
1.2.3 Clinical Treatment of Alzheimer’s Disease
Most drugs on the market today provide symptomatic relief but do not affect 
Alzheimer’s disease progression. For example, acetylcholinesterases such as Donepezil 
act on the central nervous system by inhibiting acetylcholinesterase, an enzyme that 
breaks down the neurotransmitter acetylcholine [53]. By inhibiting the enzyme that 
breaks down the neurotransmitter acetylcholine, acetylcholine remains free to interact 
with postsynaptic neuron(s) allowing the nervous signal to propagate further. Such drugs
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have been proven to temporarily provide cognitive benefit, slow functional decline, and 
help behavioural symptoms [54-57], Other acetylcholinesterase drugs approved by the 
FDA are Galantamine, Rivastagmine, and Tacrine that provide a similar mechanism of 
action as Donepezil. However, affected individuals eventually begin to demonstrate the 
same cognitive decline as other individuals not on a clinical drug treatment.
Another class of AD drug is a blocker of /V-methyl-D-aspartic acid glutamate 
receptors (NMDARs). Memantine is a drug that partially blocks the NMDAR and 
prevents excess stimulation of the glutamate system, which influences memory and 
learning [58], To date, no drug has been discovered at this time to stop or reverse the 
progression of Alzheimer’s disease.
1.2.4 Alzheimer’s Disease in Canada
Alzheimer’s disease is a debilitating disease and its greatest risk factor is 
increasing age [59, 60], In Canada, as the average age of the population extends well into 
the ninth decade, there will be an increasing number of individuals afflicted with 
Alzheimer’s disease. Currently, this number stands at half a million people, and within a 
generation this number is expected to at least double to over one million [61]. The direct 
and indirect costs for treating individuals with Alzheimer’s disease and the monetary 
wage losses for their family members is expected to surpass the $150 billion dollar mark 
within one generation [61]. Studies around the world have also indicated that as the 
severity of the disease increases, so do the associated costs with taking care of these 
individuals [62-64], Alzheimer’s is more than just an important health concern, it has the 
potential to overwhelm the Canadian health care system and may become the highest 
economic, social and health cost burden of all diseases. As a result, prevention, early
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detection, and treatment have become a top healthcare priority of many nations around 
the world, including Canada.
1.2.5 Challenges to Early Detection of Alzheimer’s disease
The fundamental challenge to early diagnosis of Alzheimer’s disease is that the 
disease is currently defined histopathologically by confirmation of neuritic plaques and 
tangles in the post-mortem brain, but the diagnosis is made based upon clinical 
symptoms. There is an assumption made about the causal linkage between the 
histopathology and the cognitive symptoms. Another assumption is that the correlation 
between pathology and symptoms can be measured accurately and reliably with currents 
cognitive tests. However, many studies have questioned these assumptions and have lead 
researchers to conclude that the current diagnostic criteria based on the National Institute 
of Neurological and Communicative Disorders and Stroke-Alzheimer’s Disease and 
Related Dementia Association (NINCDS-ADRDA) criteria and the Diagnostic and 
Statistical Manual of Mental Disorders, 4th edition (DSM-IV) criteria are inadequate for 
guiding clinical care and evaluation of therapeutic drugs. In addition, there is evidence 
that irreversible damage has already occurred by the time symptoms appear [65]. Thus, 
new biomarkers must be developed and validated to measure effects directly related to the 
disease process. Yet, there are several difficulties to the rapid development of 
biomarkers: 1) an incomplete understanding of the Alzheimer’s disease process, 2) the 
complexities related to the comorbidities of other types of dementia (i.e. vascular 
dementia) that have similar symptoms to Alzheimer’s disease, and 3) the cost associated 
with biomarker development and validation.
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Currently, several types of potential imaging biomarkers have been developed for 
the early detection of Alzheimer’s disease. Molecular probes differ in sensitivity and the 
imaging technique(s) used to detect a biological change within the Alzheimer’s brain. 
For instance, the Pittsburgh B compound (PIB) preferentially binds to |3-amyloid plaques 
in the brain and was designed with both a fluorescence tag and radionuclide for positron 
emission tomography (PET) scanning [66], In the pre-clinical stage of development, 
researchers utilized multi-photon confocal imaging to visualize the distribution of the 
compound within the transgenic Alzheimer’s disease mouse. In the clinical phase, they 
were able to inject normal elderly controls and Alzheimer’s disease patients with the 
compound and visualize uptake of compound in the brain using PET imaging [67], 
Subjects with Alzheimer’s disease demonstrated a significant uptake in the brain 
compared to normal elderly controls. Consequently, this compound can provide 
additional information to physicians to help increase diagnostic accuracy in an individual 
with Alzheimer’s disease. The development of this compound provides an example 
where both fluorescence and PET imaging were used to objectively evaluate the 
biomarker’s capabilities in detecting (3-amyloid plaques. Although proven successful at 
detecting (3-amyloid plaques, the PIB compound ability to accurately predict pre-clinical 
AD in human patients is still under investigation.
1.2.6 Pre-Clinical Models of Alzheimer’s Disease
1.2.6.1 Cellular Models of AD
Pre-clinical cellular experiments provide the stepping-stone to in-vivo animal- 
based experiments. Cellular models of diseases allow for the examination of biological 
events at the molecular level. Our laboratory choose to work with the SN56 neuronal cell
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line, a fusion between septal neurons and neuroblastoma cells [68]. Once these cells have 
been differentiated, they highly resemble neurons as they exhibit many cholinergic 
properties (Figure 1.1) [69, 70]. The goal of creating medial septal neurons was to 
immortalize cholinergic neurons from the nucleus basalis of Meynert. This is a group of 
neurons that are affected in AD [71, 72].
Figure 1.1: SN56 neuronal cell culture as seen from a brightfield light image (63x lens). 
Neuronal morphology and neurite extensions are well developed in cell culture.
1.2.6.2 Mouse Models of AD
Mouse models of disease provide us with an important understanding of not only 
the mechanisms of disease but also provide an opportunity to test disease modification 
through treatment. Differences between mice and humans are just as important as the 
similarities. Mice are small, prolific, and scientists are able to manipulate their genes to 
mimic a disease which is not possible with humans. Transgenic mice are genetically
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modified model such that the condition or disease has been induced via the manipulation 
of the genetic code. These mice provide a platform to test new treatments and the 
monitoring of those treatments. Some drugs need to be rigorously tested in animal 
models in order to move to human clinical trials. For example, immunization against 
amyloid plaques in mice showed that plaques could be cleared from the brain [73], As a 
result, mouse models of Alzheimer’s disease may offer insight into the pathological 
mechanisms as well as new drug discoveries.
Many mouse models of Alzheimer’s disease contain one or more genetic 
mutations that lead to excessive plaque formation. Amyloid Precursor Protein (APP) and 
Presenilin-1 and -2 (PS1, PS2) are genes discovered to cause early onset Alzheimer’s 
disease in humans [74], Although early onset is a small minority of all Alzheimer’s 
disease cases, it provided researchers the opportunity to further study the biological 
mechanisms behind Alzheimer’s disease pathology. For instance, at 12 months of age, 
transgenic APP/PS1 mice exhibited extensive plaque deposition within the hippocami as 
seen on Figure 1.2. Another variant of the presenilin-1 mutation is the deletion of the 
exon 9 (dE9) within the presenilin-1 gene. This caused early neurofibrillary tangles and 
plaques to form within the brains of humans [75]. Many mouse models of AD continue 
to be created and although the complete mechanism has yet to be discovered, important 
insights have been provided into the pathobiology of AD. Therefore, utilizing transgenic 
mouse models will continue to be important to understanding disease progression and 
advanced drug development to effectively treat AD.
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Figure 1.2: Amyloid plaque (black) staining in the hippocampus of a 12 month-old 
transgenic mouse stained using an antibody to P-amyloid protein.
1.2.7 Biomarkers of Disease
Biological markers may indicate a variety of disease characteristics, from the level 
of exposure to an environmental or genetic trigger, a process of the disease itself, an 
intermediate stage between exposure and disease onset or an independent factor 
associated with the disease but not directly contributing to the pathology. Specific 
biomarkers may be designed to identify the risk of developing a disease, aid in identifying 
disease, or predict future disease progression such as response to therapy.
According to the National Institutes of Health (NIH), a biomarker is “a 
characteristic that is objectively measured and evaluated as an indicator of normal 
biologic processes, pathogenic processes, or pharmacological responses to a therapeutic 
intervention.” The ideal biomarker would meet this criterion and in addition be non-
invasive and cost-effective. In order for these biomarkers to be designed, tested, and
13
developed, pre-clinical models of diseases should be utilized prior to human clinical 
trials.
1.3 Molecular Imaging of Contrast Agents
1.3.1 Contrast Agents in Imaging
The purpose of utilizing contrast agents is to enhance or highlight specific areas 
on an image. More specifically, contrast agents change the properties of the tissues or the 
surrounding areas to increase the contrast on medical images. For example, gadolinium 
changes the properties of water by causing it to relax faster than the surrounding tissue, 
thus leading to a brighter signal on a Ti-weighted image [76]. Similarly, fluorescence 
based contrast agents allow tracking of agents at the cellular level and the ability to 
observe many molecular interactions [77, 78],
1.3.2 Non-Specific and Targeted Contrast Agents
Contrast agents may accumulate in tissue due to leakage of the vasculature, or 
they may be targeted to specific cellular constituents and therefore accumulate where 
over-expression occurs. Gadolinium-based contrast agents are an example of a non­
specific contrast agent that after injection into the bloodstream, it will diffuse into a 
particular tissue or organ only when there is a perforation or increased permeability 
within the blood vessels walls [79], It normally continues to circulate throughout the 
body and will be eventually filtered and excreted by the kidneys.
Specific contrast agents have a molecular component that enables them to 
recognize enzymatic, receptor, cellular, tissue or organ targets. The addition of a specific 
ligand allows the contrast agent to be recognized by a particular biological object.
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Identification of viable targets is often a significant challenge, and determination of 
optimal amino acid ligands with the highest affinity for the biological target often takes 
considerable effort. To further our understanding of molecular and pathological events, 
specific contrast agents may be imaged to improve our understanding of these processes.
1.3.3 Multi-Modality Contrast Agents for Disease Detection
Imaging modalities can be broadly divided into primarily anatomical and 
primarily molecular imaging techniques. Anatomical imaging technologies such as 
computed tomography (CT), MRI (with contrast agents injected at millimolar blood 
concentrations) and ultrasound, are characterized by high spatial resolution. However, 
they also share the limitation that these technologies are often unable to detect disease 
until gross tissue structural changes, for example, cerebral atrophy in AD patients, are 
present. Molecular imaging modalities such as optical imaging, PET and SPECT (with 
radiotracers injected at nanomolar blood concentrations) offer the potential to detect 
minute molecular and cellular changes associated with disease. In this case, often before 
the atrophy causes visible structural changes. However, these modalities suffer from a 
poor spatial resolution with currently available technology.
Combining the strengths of anatomical and molecular imaging modalities (using 
multimodality hardware and/or co-registration post-acquisition processing) allows the 
detection of pathophysiological changes in early disease phases with high structural 
resolution. Other technologies such as high-resolution multidetector and dual-source CT 
technology with high temporal resolution and volumetric reconstruction capabilities, 
dynamic contrast enhanced MRI and CT, as well as magnetic resonance spectroscopy 
(MRS) are blurring the distinction between morphological and molecular imaging by also
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providing functional information. These technologies may change the current primarily 
technology-driven approach of diagnostic imaging into a more disease-oriented approach 
for both basic research and clinical application. Some novel contrast agents have also 
been designed for use with two or more imaging modalities. A few examples includes the 
PET/CT/MRJ contrast agent for atherosclerotic lesions [80] and similar high-density 
lipoprotein nanoparticles [81].
1.3.4 Contrast Agents for Enzymatic Activity
Many novel contrast agents have been designed to detect a biological target to aid 
in disease detection or observation. Specifically, imaging probes with enzymatic 
recognition incorporated into their molecular design are gaining popularity. Enzymes are 
proteins that help facilitate biochemical reactions. Proteases are specific kinds of 
enzymes that recognize and cleave specific substrates [82]. Substrates are the compounds 
that undergo a change after being worked on by the enzyme to yield products. The 
induced-fit theory of enzyme-substrate interaction describes how enzymes are able to 
accommodate several types of substrates within their active sites. The active site is where 
the enzymatic cleavage of a substrate occurs [83], More importantly, an enzyme will 
usually only recognize amino acids with a particular sequence and therefore can be 
targeted by a contrast agent that incorporates this sequence into the design of the agent. 
Typically an enzyme-substrate interaction lasts for microseconds after which the enzyme 
is ready to cleave the next substrate. As a result, substrates designed to detect enzymatic 




Fluorescence imaging has become a powerful and common technique throughout 
the life sciences [84, 85], This imaging modality has the capability of imaging molecular 
events due to the extremely high detection sensitivity [86], Fluorescence occurs when a 
fluorochrome or a fluorophore absorbs energy from an external source, for example from 
a laser, then emits parts of this absorbed energy as light of another colour [87]. There are 
three main steps in the fluorescence process. First, excitation of electrons occurs. 
Electrons are raised to a higher energy level and vibrational excited state due to the 
absorption of energy from a photon of light. Next, in the transitional state, the excited 
electrons may lose some vibrational energy to the surrounding environment and decrease 
to a lower excited state. Lastly, the emission phase occurs where we observe 
fluorescence. At the lowest excited state, electrons are able to give off the rest of their 
energy to return to the ground state emitting the absorbed energy as fluorescent light. 
Since less energy is emitted than absorbed due to the transition step, the emitted light is 
always of longer wavelength than the excitation light. This is known as Stokes Law [87], 
A fluorochrome can be excited with different wavelengths within its excitation spectrum 
and subsequently emits light within a characteristic range of wavelengths referred to as 
the emission spectrum. The amplitude of the emission spectrum is determined by the 
efficiency of excitation.
Fluorescent imaging continues to dominate cellular and tissue imaging because of 
its high spatial resolution, its compatibility with standard microscopy techniques and 
hardware, and its ability to detect small concentrations of fluorescent compounds or 
fluorescently tagged proteins. As a result, many multi-modality probes or contrast agents
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are still being synthesized with fluorescent imaging in mind to capitalize on the high 
sensitivity of fluorescent imaging [88-93],
1.4.2 Laser Scanning Confocal Microscopy
Laser scanning confocal microscopy has an advantage over normal widefield 
microscopy because the light can be collected from a single plane, which could be several 
microns thick [94], The optical sectioning is accomplished by a pinhole placed in the 
emission pathway at a position where only emission originating from the focal plane is 
able to pass through the detector and out-of-focus emission is blocked. This technique 
allows for the precise capture of information at the molecular level.
1.5 Magnetic Resonance Imaging
Magnetic resonance imaging provides a non-invasive method of looking into the 
structures of the brain. Unlike fluorescence imaging, it is easily possible to acquire stacks 
of images with a specified slice thickness. It is possible to acquire images of any region 
of the body as long as the region of interest fits inside the magnet, gradient coil, and radio 
frequency coil, and a homogeneous magnetic field can be achieved throughout the tissue. 
MR imaging can report both spatial and temporal information related to contrast agent 
uptake. MR imaging also provides excellent tissue contrast in the brain and other soft 
tissues, which makes MRI an ideal imaging modality of complex structures. However, to 
contrast with fluorescent imaging, the spatial and temporal resolution is decreased.
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1.5.1 MRI Contrast Agents in Molecular Imaging
Molecular imaging is a rapidly emerging field of diagnostic medicine that 
combines the disciplines of biology, chemistry, medicine, and radiology. It enables 
physicians and researchers to visualize biological processes in a non-invasive way, 
observing the biology in action. The potential to use molecular imaging to diagnose 
diseases is limitless, however the current primary uses are for the diagnosis for cancer, 
cardiovascular, and neurological diseases.
There are many types of contrast agents available for use in magnetic resonance 
imaging. The contrast agent chosen depends upon the desired contrast within the image. 
For example, iron-labeled particles appear as dark voids on T2-weighted magnetic 
resonance images and may be observed by histology to enter tissues or cells [95]. 
Paramagnetic metals such as gadolinium are substances that contain one or more unpaired 
electrons and have a positive magnetic susceptibility. The unpaired electrons interact 
with nuclear spins and cause increased rates of relaxation (1/Ti or I/T2). Gadolinium is 
also a lanthanide or “rare earth” metal that has 7 unpaired electrons giving it a relatively 
large magnetic moment. The most common clinically used contrast agent are those that 
shorten the Ti relaxation time constant of water, increasing signal intensity in T|- 
weighted images in tissue regions where the agent accumulates. A more recently 
developed mechanism of generating contrast in MRI is utilizing Chemical Exchange 
Saturation Transfer (CEST) [96-99]. The advantage of utilizing these CEST based 
contrast agents is the ability to turn them on and off at will. Therefore, multiple contrast 
agents may be used at the same time but their modulation of image signal intensity could 
be turned on when required. This method of imaging would unlock many opportunities 
to explore the way the human body works using contrast agents.
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1.5.2 MR Physics and Spin
Conventional magnetic resonance imaging utilizes the magnetic properties of the 
proton ('H), which is the most abundant nucleus in the human body [100]. A simplified 
conceptualization of the way that the MR signal is produced is described below. Each 
hydrogen nucleus is can be thought of as spinning on its axis and therefore producing a 
rotating positive charge. The laws of electromagnetism state that a moving charge 
induces a magnetic field. Thus, the hydrogen nucleus creates its own tiny magnetic field 
called a magnetic moment. In the absence of an external magnetic field, each proton 
spins about an axis oriented in random directions. However, when an external magnetic 
field is applied to these protons, individual nuclei will experience a force that causes the 
spin to align either parallel or anti-parallel with this magnetic field. There is a slight 
excess of spins that align parallel to the magnetic field [100].
Although each nucleus experiences a force from the external magnetic field, they 
do not fully align with this magnetic field. As a result, they precess, or spin around the 
axis of the external magnetic field. This precession may be visualized as a spinning top 
that wobbles about its centre of gravity. The frequency of precession about the external 
magnetic field is proportional to the magnetic field strength as given by the Larmor 
equation:
ooo = y Bo , Y = gyromagnetic ratio, B0 = magnetic field strength
Therefore, all protons precess at a specific frequency called the Larmor frequency when 
placed in an external magnetic field. Summing up all the magnetic moments in the 
sample produces a net magnetization in the direction of the applied magnetic field [101].
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1.5.3 Ti, T2, Proton Density Weighting and Relaxation
By exciting the magnetic moments to a higher energy level and bringing them into 
phase coherence using radio frequency pulses, and then manipulating the net 
magnetization using magnetic field gradients, maps of the spatial distribution of 'H atoms 
within the sample can be created called images. The signal intensity at each position in 
the image is determined by the number of protons (proton density), and modulated by the 
how quickly the magnetization looses coherence (T2 relaxation) and relaxes back to 
equilibrium (Ti relaxation) [102]. Specific patterns of radio frequency pulses and 
gradients can be designed called pulse sequences to generate images that are proton 
density, Ti or T2 weighted by modifying pulse sequence parameters called the repetition 
time (TR), echo time (TE) and flip angle (a). More specifically, Ti or “spin-lattice” 
relaxation and T2 or “spin-spin” relaxation occur simultaneously. Ti relaxation describes 
the recovery of the net magnetization in the direction of the external magnetic field 
direction (Bo). This relaxation is modeled by the equation:
Mz = Mz(o)[l-e(‘t/T1)] ,
Ti is time it takes for approximately 63% of the net magnetization to return to the 
Bo direction. Usually, after a length of time equal to 5x T1, the majority of the net 
magnetization has recovered back to the initial state prior to excitation. T2 relaxation 
describes the loss of the net magnetization in the transverse plane perpendicular to the 
external magnetic field (Bo) [102], The T2 is the time when approximately 37% of the net 
magnetization is still detectable in the transverse plane.
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Proton density (PD) images are acquired normally with a long repetition time and 
a short echo time [102], The long repetition time reduces the Ti weighting while the 
short echo time minimizes the T2 weighting. As a result, most of the tissues excited by 
the radiofrequency pulse have more or less fully relaxed when the signal is measured. 
Proton density images are much brighter than the corresponding Ti and T2 images 
acquired using MRJ.
All three types of contrast are present to various degrees in an MR image. 
However, depending on the anatomy that is to be examined, modifying the scan 
parameters can emphasize each of the different types of contrast of the same tissue. 
Similarly, some contrast agents are designed to be utilized in conjunction with images 
acquire that emphasize a particular contrast. For example, we have developed a novel 
Gd3+-DOTA-CAT contrast agent that is best suited for imaging using a Ti-weighted 
acquisition. The gadolinium shortens the T1 of the water surrounding the agent in which 
it resides.
1.5.4 Paramagnetic Chemical Exchange Saturation Transfer (PARACEST)
Imaging
There are other ways to change signal intensity and contrast within MR images. 
One such example is the use of frequency selective radio frequency pulses to selectively 
excite specific pools of protons within a sample that then exchange with the bulk pool of 
water that is measured. For example, one could selectively excite protons that are found 
within cell membranes and normally not visible by MRJ. This method is usually called 
magnetization transfer imaging. This idea can be extended into the realm of contrast 
agents. For example, there exists a type of MRJ contrast agent that can generate contrast
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using this mechanism of Chemical Exchange Saturation Transfer (PARACEST) [103]. 
When a paramagnetic metal is included in the agent, the potential sensitivity increases 
greatly and the agent is called a Paramagnetic CEST or PARACEST agent.
To understand how PARACEST agents work, we must consider two different 
pools of water in a sample; the bulk or free water that we measure and a separate pool of 
water bound to the PARACEST agent. Bound water refers to water molecules that are 
bound or restricted, for instance, by momentarily interacting with contrast agents. 
Because the bound water comes into close contact with the paramagnetic metal, its 
Larmor frequency is shifted providing an opportunity to selectively excite this pool 
without affecting the bulk water. The bound pool does however exchange with the bulk 
pool, and by measuring the amount of magnetization that is transferred to the bulk pool, 
we can observe the presence of the contrast agent. Several groups, including our own, 
have demonstrated this ability using several types of lanthanide metals [104-107].
1.5.5 On-Resonance Paramagnetic Chemical Exchange Effect
A similar but more sensitive method of generating image contrast was described 
by Vinogradov, et al. [108] called the On-resonance Paramagnetic Chemical Exchange 
Effect or OPARACHEE. This method is conceptually similar to the PARACEST method 
described above, but rather selective excitation of the bulk pool is used to generate 
contrast in the presence of the contrast agent. In this method, the bulk magnetization is 
perturbed in such a way that when there is no agent present, no change in signal intensity 
is observed (effectively a 360 degree pulse is applied). However when a PARACEST 
agent is present, spins that diffuse between the bulk pool and the bound pool do not 
experience the full effect of the 360 degree pulse and therefore are not fully refocused
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leading to a decrease in image signal intensity. The imaging technique has greater 
sensitivity than the PARACEST imaging technique described above, but has several 
limitations. The most significant limitation is that it is not possible to determine the 
chemical shift of the bound water protons, therefore, this approach cannot be used to 
relate signal changes to physiological properties of the sample which are normally 
modulate chemical shift. The OPARACHEE approach has been applied in-vivo to 
visualize contrast agent within the kidneys of rats [109].
1.6 Molecular Biology
1.6.1 Cell Penetrating Peptides
Cell penetrating peptides (CPPs) are short peptides that facilitate cellular uptake 
of various molecular cargo from small chemical molecules to nano-sized particles and 
large fragments of DNA [110]. The cargo is associated with the peptides either through 
chemical linkage via covalent bonds or through non-covalent interactions. CPPs typically 
have an amino acid composition containing either a high relative abundance of positively 
charged amino acids such as lysine or arginine, or have sequences that contain an 
alternating pattern of polar/charged amino acids and non-polar, hydrophobic amino acids.
The main highlighting feature about these peptides is the huge diversity of the 
transported molecules in terms of size and biological nature. For instance, the Tat peptide 
has been used to internalize liposomes, adenovirus, plasmid DNA, peptide nucleic acids, 
and paramagnetically labelled DOTA [111-117]. In addition to bringing targets 
intracellularly, CPPs have demonstrated their in-vitro and in-vivo potential by entering 
many cell types and tissues [118].
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CPPs hold great potential as in-vitro and in-vivo delivery vectors for use in 
research and medicine. Current use is limited by a lack of cell specificity in CPP 
mediated cargo delivery and insufficient understanding of the modes of their uptake 
[119]. In addition, fixation of cells on cover-slips or slides causing a re-distribution of 
CPP and their cargo [120], Therefore, experiments that involve CPP delivery must 
include live imaging data while these contrast agents are being administered.
The first CPP was discovered independently by two laboratories in 1988 when it 
was found that the trans-activating transcriptional activator (Tat) from Human 
Immunodeficiency Virus 1 (HIV-1) could be efficiently taken up from the surrounding 
media by numerous cell types in culture [121]. Since that time, the number of known 
CPPs has expanded and small molecule synthetic analogues with more effective protein 
transduction properties have been created. The first use of CPPs in crossing the blood 
brain barrier was described by Schwarze et al., in which they reported a large protein able 
to cross the BBB into significant areas of the brain [122, 123], Other studies describe 
CPPs attached to therapeutic agents for delivery across the BBB that resulted in increased 
drug efficacy [124, 125].
CPPs therefore provide a way to get the contrast agent across difficult barriers 
such as the blood brain barrier. The next section will explain in better detail the principle 
of how these agents could be targeted to accumulate in a diseased state.
1.6.2 Enzymatic Diffusion Trap of Contrast Agents
In normal control tissues, there exists a specific uptake and retention time of 
contrast agents. Uptake of contrast agents may depend on several factors including 
molecular weight, charge at physiological pH, and lipophilicity to cross the blood-brain
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barrier and ability to be taken up into cells [126], Similarly, the contrast agent 
concentration within the tissue will eventually decrease as the agent leaves by diffusion, 
export or through cell metabolism. It is difficult to discern which of the two events are 
occurring, or whether they are occurring at the same time.
In diseased tissues there is often a change in the expression of specific proteins. In 
the case of Alzheimer’s disease, there is an up-regulation of the lysosomal enzyme 
cathepsin-D. With this increased expression, greater amounts of contrast agent would be 
more likely to be recognized and cleaved by the protease cathepsin-D. Once the enzyme 
has cleaved the contrast agent, the cell-penetrating peptide portion is removed leaving it 
effectively trapped within the cell. In other words, the contrast agent would have a 
greater difficulty leaving the cell as indicated by enzymatic trap.
1.6.3 Western Blotting
Protein analysis is a useful tool to evaluate expression levels within a biological 
sample. For example, neuronal SN56 cells create an extensive number of proteins to 
function on a normal basis. The ability to extract and study individual proteins could 
provide valuable information in the cell line’s ability to grow, differentiate, and survive. 
In our case, we examined cathepsin-D protein levels as a way to: a) confirm our cellular 
transfection experiments, b) to support our hypothesis that increased cathepsin-D levels in 
SN56 cells mimics our cellular model of AD. In addition, we have extracted brain 
samples of transgenic Alzheimer’s disease mice over one year old to quantify how much 
cathepsin-D is being expressed.
Protein samples are obtained from either cell lysates or brain tissues for analysis. 
Once each sample has been extracted and quantified, the same amount of protein would
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be prepared for each sample. Proteins are then denatured and then run by sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Gel electrophoresis separates 
the proteins by size and charge by applying an electric field through a gel medium. The 
electric field attracts the overall charge on the molecule through the gel matrix. The gel 
composition acts as a molecular sieve to slow down larger molecules and as a result, they 
do not travel as far as smaller molecules. The combination of size and charge of a 
molecule and the length of time that the electric field is applied will determine how much 
separation occurs between the mixtures of proteins within a sample. Once the 
appropriately sized proteins have been separated, they are then transferred to a 
nitrocellulose membrane where antibodies are able to easily bind to the proteins [127]. 
However, the nitrocellulose membrane must be blocked by milk or bovine serum albumin 
to prevent excessive antibody binding. Primary antibodies are then added to bind to our 
protein of interest. A wash occurs here with tris-glycine buffered tween-20 (TBST) to 
remove excess primary antibody. Secondary antibodies are incubated afterwards to bind 
to the primary antibodies. A second wash occurs with TBST to remove the excess 
secondary antibodies. The secondary antibodies react with a chemical solution to provide 
signal which can then be detected using a multitude of techniques (i.e. x-ray film, 
fluorescence). The amount of protein shown upon analysis depends on how thick and 
dark the band appears. This information is utilized to quantify the amount of protein 
being expressed by the cell lysate or tissue sample. An internal loading control is utilized 
to measure how much protein exists by probing with actin or tubulin.
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Figure 1.3: Western Blot of Cathepsin-D expression in SN56 cells. The first lane was 
loaded with a sample from non-transfected SN56 cells as a negative control. The next 6 
lanes were loaded with 6-10 pg of Cat-D transfected SN56 cells. The smaller mature 
form exists at 50 kDa, the larger immature form of Cat-D exists at 73 kDa. The 
additional 27 kDa is from the mCherry fluorescent tag attached to the Cat-D protein. 
Alpha tubulin is also shown underneath as a control.
1.6.5 Histology
Histology is the study of tissues and cells at the microscopic level. After the 
injection of the dual-labeled contrast agents, the fluorescent properties of the contrast 
agent can be evaluated. The ability to observe contrast agent at the cellular level is an 
important technique so that we may evaluate its capability at crossing the blood brain 
barrier, entering tissues, cells, and organelles. Post-injection of contrast agent, the mouse 
is sacrificed after a set amount of time and then the brain is extracted and stored in 10% 
neutral buffered formalin. A coronal section through the hippocampus of each mouse 
was obtained in order to assess the amount of uptake within specific regions of the brain.
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1.7 Preliminary Work on Cathepsin-D targeted contrast agents
The following section is a brief summary of the work that has been described in a 
manuscript by: Suchy, M., Ta, R., et al. A paramagnetic chemical exchange-based MR1 
probe metabolized by cathepsin D: design, synthesis and cellular uptake studies. 2010. 
Organic & Biomolecular Chemistry. 8(11): p. 2560-6. As second author, I contributed to 
performing the cellular uptake studies, metabolic cleavage experiments and wrote the 
methods section for those experiments.
1.7.1 Contrast agent design and synthesis
The design of the novel MRI contrast agents was an idea that combined previous 
works published in the literature and a need for the early diagnosis of AD. This work 
described the synthesis and design of targeted contrast agents for cathepsin-D activity 
[128], Preliminary studies examining enzymatic recognition and cellular uptake were 
also performed. Figure 1.7 illustrates the molecular structure of the novel dual contrast 
agent. The red portion shows how the lanthanide metal is placed within a DOTA cage, 
where several different metals can be utilized depending on the type of MRI contrast 
desired. The green part of the compound is where Oregon Green, a compound that 
fluoresces when excited by the correct wavelength. The blue portion corresponds to 
amino acid sequences which can be broken down into two sections. The first portion is 
the cell-penetrating peptide (CPP) or TAT region. This region was incorporated to 
increase cellular uptake and help the contrast agent migrate across the blood brain barrier 
with greater efficiency. The next portion is the cathepsin-D recognition site which allows 
enzymatic targeting of the contrast agent. Thus, when the enzyme cathepsin-D interacts
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with the contrast agent it would cleave at the appropriate site also removing the cell- 
penetrating peptide. The remaining compound would consist of the MR and optical tags 
for imaging in either modality.
Figure 1.4: Schematic diagram of cathepsin-D targeted contrast agent. The lanthanide 
metal may be replaced depending on the type of desired MR contrast.
1.7.2 Enzymatic Recognition of Cathepsin-D Cleavage Domain
The first task in ensuring that the contrast agent was working effectively was to 
evaluate its ability at being recognized by the enzyme cathepsin-D. Studies were 
performed that combined bovine cathepsin-D enzyme and Tm -DOTA-CAT. Samples 
were incubated for 5 minutes in a buffer at a pH of 4.5, and then the addition of pepstatin 
A was required to inhibit the enzymatic actions of cathepsin-D. The samples were then 
sampled by electrospray-ionization mass spectrometry, which detects all molecular
PEPTIDE BACKBONE
Cell P*
Peptide Optical Tag 
(Oregon Green)
= Gd3+, Tm3+, etc.
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fragments and reports their respective sizes. Cathepsin-D cleaved the contrast agent 







Mass = 1906 Da
* Cleaved as predicted
Figure 1.5: Tm -DOTA-CAT reaction scheme illustrating cleavage by cathepsin-D 
enzyme. The red boxes highlight the two phenylalanine amino acids (FF) that are cleaved 
upon recognition by cathepsin-D as predicted.
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Figure 1.6: Deconvoluted electrospray-ionization mass spectrometry spectrum showing 
the molecular mass of cleaved Tm3+-DOTA-CAT of 1906 Da. This molecular size 
corresponds to the fragment without the cell-penetrating peptide region.
The size of the cleaved fragment was then examined using single mass analysis to 
determine exactly where the cleavage had taken place within the cathepsin-D recognition 
site. The outcome demonstrated that cathepsin-D had cleaved Tm -DOTA-CAT 
between two phenylalanine amino acid residues within the cleavage site. The 
experimental results were also verified and confirmed with other cathepsin-D cleavage 
sites that have found the majority of product is cleaved within the two phenylalanine 
amino acids.
1.7.3 Preliminary Cellular Uptake Experiments
'•> I
Early studies with the compound, Tm -DOTA-CAT, were performed to evaluate 
the contrast agent’s ability to be taken up and retained in neuronal SN56 cells. It was
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found that after 30 minutes of incubation with the contrast agent, SN56 cells with up 
regulated cathepsin-D retained a greater amount of the agent within the cell body. In 
SN56 cells with a normal or basal amount of cathepsin-D expression, there was very little 
to no contrast agent retained within the cell bodies. This indicated that there was a 
selective uptake of contrast agent in cells over-expressing cathepsin-D. In addition, as the 
concentration of the contrast agent increased, so did the retention of the agent over the 
concentration range (5-100 pM). Thus, neuronal SN56 cells exhibited selective and 
concentration dependent retention of Tm3+-DOTA-CAT.
DIC Cathepsin-D Tm^-DOTA-CAT Overlay
Figure 1.7: Panels A-D illustrates SN56 neuronal cells transfected with human cathepsin- 
D. The first set of panels (a and e) is the DIC image of SN56 cells. The second column 
of images (c and f) displays the fluorescence coming from the red channel. The third set 
of panels (c and g) show fluorescence obtained from the green channel. Lastly, the fourth 
panel (d and h) demonstrates the overlay of both red and green channels. The bottom row 
of images (e-h) are control SN56 cells.
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1.7.4 OPARACHEE Detection of Tm3+-DOTA-CAT
In addition to fluorescence studies of the contrast agent Tm3+-DOTA-CAT, we 
wanted to demonstrate its detection in the MRI environment. A 3 mM Tm3+-DOTA-CAT 
solution was prepared by dissolving in water and acetonitrile. Three types of solutions 
were prepared: 1) control with 80% water and 20% acetonitrile, 2) DOTA-CAT agent, 
not including the Tm3+ lanthanide metal, and 3) the Tm3+-DOTA-CAT compound after 
Cat-D cleavage. The prepared samples were then detected using on-resonance 
paramagnetic chemical exchange effect (OPARACHEE) in the 9.4T MRI scanner.
The results shown in Figure 1.11 illustrate the detection of our contrast agent in 
the MRI environment. The scale on the right hand side of the images demonstrates the 
signal intensity of each sample after a particular pulse sequence has been applied. The 
first row of samples shows the control FLASH images. The second row of samples show 
a WALTZ-16 prep image acquisition that shows a signal decrease as expected that is 
more pronounced in the third column that contains the Tm metal. The last row 
illustrates the signal intensity difference between the control FLASH and Waltz-16 
image. The final result was a 24% OPARACHEE contrast from the compound
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Figure 1.8: OPARACHEE contrast generated by Tm3f-DOTA-CAT.
To summarize, we studied the properties of the MRI, fluorescent, Cat-D 
recognition, and cell-penetrating peptide properties designed for our dual MRI/fluorescent 
probe. Enzymatic degradation studies revealed that Tmu - DOTA-CAT was a substrate 
for Cat-D, where mass spectrometry studies confirmed cleavage between the two 
phenylalanine residues. Fluorescence-based studies demonstrated selective intracellular 
uptake in cells that over-expressed Cat-D. The cleavage of the protease domain removes 
the CPP allowing the probe to accumulate within cells increasing the retention time. 
Lastly, in-vitro MRI contrast was achieved using the OPARACHEE method. These
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preliminary results demonstrate the potential utility of this MRI/fluorescent contrast 
agent.
1.8 Summary
This chapter discussed the wide range of chemical and biological applications that 
exist for MR1 contrast agents. Contrast agent enhanced MRI could become an invaluable 
tool for the diagnosis of Alzheimer’s disease and many other conditions. The 
development of molecular imaging may also have specific application to drug 
development in animal models of disease. With improved targeted delivery of these 
agents, the ability to diagnose diseases will become more sensitive, precise, and objective. 
Finally, contrast agents that detect biological phenomena by altering the intensity of 
signal enhancement in a conditional fashion are steps toward unravelling the complexity 
of biological systems. Further, these agents represent the introduction to complete, non- 
invasive, medical examinations that are safe, fast, and accurate.
1.8.1 Scope of Thesis
The testing and development of advanced MRI contrast agents is the focus of this 
thesis. Clinically used contrast agents aid in the visualization of the extracellular space or 
blood pool in MRI. To extend the usefulness of these contrast agents, the chemistry was 
modified to develop agents that are sensitive to biological events and directed to cellular 
targets. These two improvements are closely related in that many biologically significant 
molecules are located in specific parts of the body, cell, or tissue. An introduction into 
Alzheimer’s disease, the field of MRI, fluorescence imaging, and contrast agents is
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presented in Chapter 1 along with a preliminary description of our developing contrast 
agent. Chapter 1 proceeds to outline previous literature attempts at target-specific 
delivery of contrast agents and the development of biologically sensitive contrast agents. 
Chapter 2 will describe further characterization and testing of contrast agents in cell 
culture and in-vivo. This work was taken from the manuscript submitted to Contrast 
Media and Molecular Imaging entitled, A Dual Magnetic Resonance Imaging (MRI) / 
Fluorescence Contrast Agent for Cathepsin-D Detection. The final chapter will provide a 
framework for future studies and the upcoming role of contrast agents in AD.
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Chapter 2: A Dual Magnetic Resonance Imaging/Fluorescent 
Contrast Agent for Cathepsin-D Detection1
2.1 Introduction
Alzheimer disease (AD) is the most common neurodegenerative disease in adults 
and afflicts 17 million people worldwide [1], Currently, there is no approved biomarker 
available for early detection and diagnosis must be made clinically once symptoms are 
apparent [2, 3], However, the pathological changes of AD are believed to begin more 
than a decade before the development of symptoms, and irreversible damage may already 
be present at the time of diagnosis [4], Therefore, validated biomarkers to objectively 
screen for pre-clinical AD are critically needed.
One potential early marker for AD is Cathepsin-D (Cat-D), a ubiquitously 
expressed aspartic protease [5, 6], Cat-D is a protease that resides in lysosomes, which 
are specialized sub-cellular compartments responsible for the degradation of proteins, 
lipids and carbohydrates. Proliferation of lysosomes has been reported to be one of the 
earliest histopathological changes in AD, occurring before the appearance of classical 
neuropathological changes such as amyloid plaque deposition [7]. This proliferation is 
accompanied by massive upregulation of lysosomal enzymes including Cat-D such that 
with advancing disease, Cat-D staining eventually fills neurons [8], Amyloid plaques 
also contain high levels of biochemically active lysosomal enzymes including Cathepsins 
B and D [9-11], Cat-D has been shown to be upregulated in the cerebrospinal fluid of 
subjects with AD [12], in subjects with Familial AD mutations, and in mouse models of 
AD [13-15]. Asa result, Cat-D may be an excellent target for the early detection of AD.
1 A version of Chapter 2 was submitted to Contrast Media and Molecular Imaging on September 7th, 2011
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Although many other imaging modalities exist, in-vivo imaging of protease 
activity by magnetic resonance imaging (MRI) would provide the widest potential clinical 
benefit due to the wide spread use of MRI scanners. MRI does not expose patients to 
radiation, and would allow the detected contrast to be imaged and automatically 
registered with the in-vivo anatomical, functional, and chemical information accessible by 
MRI [16-18],
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Figure 2.1: Molecular structure of Gd3 -DOTA-CAT and Tm3 -DOTA-CAT. An 
imaging moiety consisting of a metal chelator (with Gd or Tm lanthanide metal) for 
MRI detection (red) and an Oregon Green (green) fluorescent tag for optical detection. 
This is coupled to a peptide backbone consisting of a cathepsin-D cleavage sequence and 
a cell-penetrating peptide sequence.
We have previously reported the synthesis of a dual MRI/fluorescent contrast 
agent for the detection of Cat-D activity [19] (Figure 2.1). This compound consists of an
O i
MR imaging moiety that includes a caged lanthanide metal, such as Gd to produce Ti- 
weighted MRI contrast or Tm to produce MRI contrast by PARAmagnetic Chemical
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Exchange Saturation Transfer (PARACEST) [20, 21]. Oregon Green is also incorporated 
for optical detection [22], These imaging moieties are conjugated to a peptide backbone 
containing a Cat-D cleavage site and a Tat sequence derived from the HIV virus that 
enhances penetration through cell membranes and across the blood brain barrier (BBB) 
[23], In this strategy, the Tat peptide facilitates transport of the entire molecule across the 
BBB both into and out of the central nervous system. In the presence of elevated levels 
of Cat-D, cleavage of the agent at the Cat-D cleavage site will release the Tat peptide, 
trapping the MR visible/Oregon Green components inside the BBB or cell [19]. This 
approach to contrast agent design is similar to the strategy proposed by Roger Tsien’s 
group in conjunction with optical labels and is conceptually similar to the process used in 
Positron Emission Tomography (PET) imaging that allows flourodeoxyglucose (FDG) to 
accumulate in cells as FDG-6-P. One major advantage of this method is that a single Cat- 
D molecule can cleave multiple contrast agent molecules leading to accumulation of the 
contrast agent inside the BBB or cell, with a resulting amplification of the observed 
signal.
We have previously demonstrated that Tm -DOTA-CAT is a substrate for Cat-D 
and it is taken up and retained by cells over-expressing Cat-D [19]. Although Tm - 
DOTA-CAT can be detected using the On-resonance PARAmagnetic Chemical Exchange 
Effect (OPARACHEE) [24], the inclusion of Gd3+ in the agent may increase in-vivo 
detection sensitivity using Ti-weighted MR imaging. The purpose of the current study 
was to determine the minimum concentrations required for optical and MR detection, and 
establish the time course of cellular uptake and retention in the brain in normal mice and
mouse models of Alzheimer’s disease.
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2.2 Methods
2.2.1 Magnetic Resonance Imaging
To study the Tj effect of agent concentration on image contrast, a series of 10% 
(w/v) heat-treated (samples heated in an 80 °C water bath for 10 minutes) Bovine Serum 
Albumin (BSA; Sigma Aldrich, St. Louis, MO) tissue phantoms containing a range of
I
Gd -DOTA-CAT concentrations (0-500 pM) were prepared as in [25]. This agent was
n i
compared to the standard and widely used contrast agent Gd -DTPA (Bayer Healthcare 
Pharmaceuticals Inc., Germany) in 10% BSA as above. Ti-weighted images of the 
phantoms were acquired on a 9.4 Tesla small animal MRI scanner (Agilent, Palo Alto, 
CA) using a spin-echo Ti-weighted pulse sequence (field of view = 38.4 x 38.4 mm , data 
matrix: 192 x 192, repetition time = 50 ms, echo time = 14 ms, 2 averages, 2 dummy 
scans, 200 pm resolution) at 37°C. The T| time constants were measured using an 
inversion prepared spin-echo multi slice pulse sequence (TE = 14 ms, TR = 50 ms, TI = 
0, 10, 20, 40, 80, 160, 320, 640, 1280, 2500 ms, 2 averages, 2 dummy scans). The Ti 
time constant of each solution was measured by fitting a single exponential curve to the 
signal intensity as a function of the inversion times (TI). The inverse of the longitudinal 
relaxation time (Ri = 1 / Ti) was plotted against concentration and fit to a straight line to 
estimate the relaxivity.
2.2.2 Detection Limit of Tm3+-DOTA-CAT and Gd3+-DOTA-CAT by Optical 
Imaging
To determine the emission peak, emission spectra were obtained at 5 nm intervals 
for samples of 50 pM FITC-dextran (Sigma Aldrich, St. Louis, MO), 1 mM Tm3+-
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DOTA-CAT, and 1 mM Gd3+-DOTA-CAT excited at 488 nm. Serial dilutions of both 
compounds were performed to create a range of concentrations (1 nM - 10 pM). All 
samples were prepared in a 96-well black plate (Coming Costar, Lowell, MA) in 
triplicate, sampled by SpectraMax5 (Molecular Devices, Sunnyvale, CA) and analyzed by 
SoftMax Pro data analysis software (Molecular Devices, Sunnyvale, CA).
2.2.3 Cell Culture
SN56 cells were a gift from Dr. Jane Rylett (The University of Western Ontario). 
SN56 cells were derived from septum neurons (Septal neurons X neuroblastoma 
N18TG2) [26] and present a number of neuronal features including expression of synaptic 
vesicle proteins [27] and neuronal type calcium channels. These features are increased by 
differentiation [28, 29], Cells were maintained in Dulbecco's modified Eagle's medium 
(Gibco) supplemented with 5% fetal bovine semm (HyClone) and 1% 
penicillin/streptomycin (Gibco). Cell differentiation was performed with the addition of 1 
mM dibutyryl-cyclic AMP in the same medium without fetal bovine semm for 24 hours. 
Transient transfections were performed with plasmid expressing a Cat-D-mCherry fusion 
protein using Lipofectamine 2000 Reagent (Invitrogen) according to manufacturer's 
instructions as previously described [30],
2.2.4 Cellular Uptake and Confocal Microscopy
SN56 cells were grown in 35-mm glass-bottomed culture dishes (MatTek 
Corporation, Ashland, MA). SN56 cells were incubated at 37 °C for 30 minutes with 50
i  I
pM Tm -DOTA-CAT added to cell culture media. Cells were washed three times with 
hanks buffered saline solution (HBSS; Invitrogen) and imaged using a Zeiss LSM 510-
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Meta laser-scanning confocal microscope (Carl Zeiss, Germany) using a 63X 1.4 
numerical aperture oil immersion lens. The contrast agent was visualized using a 488 nm 
excitation laser and a 500-530-nm emission band pass filter set. Red fluorescence from 
the Cat-D-mCherry fusion protein was imaged using a 543 nm excitation laser and long 
pass 560 filter set. Uptake was quantified by counting the number of cells that had 
clearly taken up green fluorescent Tm -DOTA-CAT by an observer blinded to their Cat- 
D expression. At least 277 cells were counted from three independent uptake 
experiments.
2.2.5 Western Blotting and Antibodies
All cell and tissue lysates were prepared using protease cocktail inhibitors (Roche, 
Mississauga, ON) with pepstatin A. Lanes were run with 20 pg of protein on a 12% 
SDS-polyarcylamide gel and the resolved proteins were semi-dry transferred to a 
nitrocellulose membrane (Bio-Rad, Mississauga, ON) using a Trans-Blot® Semi-Dry 
Electrophoretic Transfer Cell (Bio-Rad, Mississauga, ON). The membrane was soaked 
with 5% non-fat milk (w/v) dissolved in tris-glycine buffered saline tween-20 (0.05% 
TBST) to block free protein binding sites. Blots were probed using Anti-Cat-D antibody 
(Santa Cruz Biotechnology, Santa Cruz, CA), and detected using rabbit-anti-goat coupled 
to horseradish peroxidase using enhanced chemiluminescence and exposed to CL- 
Xposure film (Thermo Scientific). Blots were re-probed with anti-Alpha-tubulin (Sigma 
Aldrich, St. Louis, MO) as a loading control. Since immature Cat-D is also the active 
form and performs the same enzymatic functions as the mature form, both forms were 
grouped into a total Cat-D expression [5], Films were scanned and quantified using 
ImageJ (http ://rsbweb .nih. gov/ij /).
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2.2.6 Cell Viability Studies
SN56 cells were seeded in 12-well plates and incubated overnight before 
treatment of 50 pM Tm3+-DOTA-CAT. Following the indicated incubation time (0, 2, 4, 
6, 24 hrs), cell density and viability were determined by 0.4% trypan blue exclusion in 
triplicate. Light microscope images were acquired (lOx lens) in 5 random areas within a 
well and cell counting was performed.
2.2.7 Mice
All animal studies were conducted in accordance with the guidelines of the 
Subcommittee on Animal Care at the University of Western Ontario, and conformed to 
the Canadian Council on Animal Care guide for the care and use of laboratory animals. 
One year old APP-Swedish/PSl-dE9 transgenic Alzheimer’s disease mice (Jackson 
Laboratories, Bar Harbour, ME) and age-matched controls BL/6 (Jackson Laboratories, 
Bar Harbour, ME) were a gift from Dr. Marco A.M. Prado and Vania Prado (The 
University of Western Ontario). These double transgenic mice express a chimeric 
mouse/human amyloid precursor protein bearing a Swedish mutation 
(Mo/HuAPP695swe) and a mutant human presenilin 1 with a deletion in exon 9 (PS1- 
dE9) and develop amyloid plaques after the age of 6 months [31].
2.2.8 Contrast Agent Uptake in PSl-dE9 and Control Mouse Brain Tissues
Mice were anaesthetized with 4% isofluorane and oxygen (1 L/min). A tail-vein 
catheter was established and a saline flush was performed to ensure the catheter was 
accurately placed. Mice were injected intravenously with 100 pL of 1 mM Tm -DOTA- 
CAT over four minutes using a Harvard Apparatus PHD 2000 programmable pump
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(Instech Laboratories, Plymouth Meeting, PA). Post-injection, mice were sacrificed at 30 
minutes (n = 3), 60 minutes (n = 3), 120 minutes (n = 3) and the brain was extracted. The 
prefrontal cortex was removed, placed on dry ice and stored at -80°C for western blotting. 
The rest of the brain was fixed in 10% neutral buffered formalin for at least 48 hours.
2.2.9 Histological Analysis of Transgenic PSl-dE9 and Control Mice
Mouse brains were paraffin embedded and sectioned into 5 pM thick coronal 
sections. To detect Cat-D, sections were processed using a 2100 Retriever (Pick Cell 
Laboratories, Lelystad, Netherlands) and stained with antibodies against Cat-D (Santa 
Cruz Biotechnology, Santa Cruz, CA). Antibodies were detected using an AlexaFluor 
543 (red) anti-rabbit secondary for immunofluorescence (Molecular Probes) and nuclei 
were counterstained with DAPI (Sigma-Aldrich, St. Louis, MO). Sections were imaged 
by confocal microscopy on a Zeiss LSM 510 META laser-scanning confocal microscope 
(Carl Zeiss, Germany) using a 63X 1.4 numerical aperture oil immersion lens. The 
contrast agent was visualized using a 488 nm excitation laser and a 500-530-nm emission 
band pass filter set. Red fluorescence from Cat-D was imaged using a 543 nm excitation 
laser and long pass 560 filter set. Blue fluorescence from DAPI staining was imaged 
using a 2-photon Chameleon excitation laser at 750 nm and 390-465 nm emission band 
pass filter set. Because the green contrast agent signal was quite diffuse, the confocal 
slice thickness was increased to 10 microns. Mean pixel intensity was analyzed across 
the image for each time point using Photoshop (Adobe) and ImageJ 
(http://rsbweb.nih.gov/ij/). Mean pixel intensity levels were assigned to each group and 
their respective time points expressed as mean ± SEM. Each set of images were acquired 
on the same day and with identical acquisition settings.
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To examine the uptake within the cortex, CA1, and CA3 regions of the 
hippocampus, non-injected mean pixel intensity values were subtracted from control- 
injected and PSl-dE9 injected mean pixel intensity values. Two-tailed paired t-tests were 
performed using Prism5, (GraphPad, La Jolla, CA) to compare the mean pixel intensity in 
images between control-injected and PSl-dE9 injected mice at each time point (p < 0.05).
2.3 Results
2.3.1 In-Vitro MRI: Ti Relaxivity of Gd3+-DOTA-CAT
We examined the relative Ti-weighted signal intensities from phantoms 
containing a range of concentrations of Gd3+-DOTA-CAT and conventional Gd3+-DTPA 
in 10% bovine serum albumin at 9.4T at 37°C (Figure 2.2A). Both agents showed a 
concentration-dependent increase in Ti signal intensity with Gd3+-DOTA-CAT generating 
higher signals than Gd3+-DTPA, indicating more efficient Ti relaxation with this agent. 
The Ti relaxation time constant of each compound at concentrations ranging from 50 pM 
to 500 pM were studied. Gd3+-DOTA-CAT had a lower Ti time constant at each 
concentration compared to Gd3+-DTPA. Plotting the relaxation rate (Ri = 1 / Ti) as a 
function of concentration (Figure 2.2B), Gd3+-DOTA-CAT had a relaxivity of 6.9 
(mM-s)"1 compared to 3.2 (mM-s)'1 for Gd3+-DTPA at 9.4 Tesla. The R2 of the slopes 
were 0.99 and 0.98 for Gd3+-DTPA and Gd3+-DOTA-CAT respectively. The 95%
♦ I 1confidence intervals for the slope of Gd -DTPA was between 2.7 and 3.6 (mM-s) 
compared to the slope for Gd -DOTA-CAT, which was between 4.5 and 9.3 (mM-s) . 
Therefore, Gd3+-DOTA-CAT is expected to generate greater signal changes in Ti- 
weighted MRI than commercially available Gd3+-DTPA at 9.4 Tesla.
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Figure 2.2: In-Vitro MRI of Gd3+-DOTA-CAT. Spin Echo Multi Slice (SEMS) Tl- 
weighted image of various concentrations of Gd3+-DTPA and Gd3+-DOTA-CAT in 10% 
BSA, and 10% BSA alone acquired at 37°C at 9.4T. Echo time = 14 ms, repetition time = 
50 ms, 2 averages, 2 dummy scans, 200 pm resolution. (B) Relaxation rate (Ri = 1/Ti) 
as a function of concentration. Linear best fitted curves are displayed. Gd3+-DOTA-CAT 
has a greater relaxivity 6.9 (mM-s)"1 than clinically used Gd3+-DTPA.
2.3.2 Fluorescence Detection of Tm3+-DOTA-CAT and Gd3+-DOTA-CAT
To examine the fluorescent characteristics of the agents, we generated 
fluorescence intensity curves of Tm3+-DOTA-CAT and Gd3+-DOTA-CAT plotted against 
their concentrations (Figure 2.3A). FITC-dextran was included as a control. The peak 
emission for FITC-dextran, Tm3+-DOTA-CAT and Gd3+-DOTA-CAT was 525 nm (data 
not shown). Both Tnr3+-DOTA-CAT and Gd3+-DOTA-CAT were clearly detectable at 1 
nM concentration. There was a significant difference between the blank control and each 
concentration of Tnv3+-DOTA-CAT (p < 0.05). Figure 2.3B shows an expanded scale in 
the nanomolar range of both agents. As expected, FITC-dextran exhibited greater 
fluorescence intensity than Tm3+-DOTA-CAT and Gd3+-DOTA-CAT, reflecting the 






Figure 2.3A: Fluorescent detection of Tm3+-DOTA-CAT and Gd3+-DOTA-CAT. (A) 
Fluorescence intensity of FITC-Dextran, Tm3+-DOTA-CAT and Gd3+-DOTA-CAT was 
determined in the concentration range of 1 nM to 10 ¡aM. FITC-Dextran, Tm3+-DOTA- 
CAT and Gd3+-DOTA-CAT data were fitted to a polynomial function. There are six data 






Figure 2.3B: Expanded scale of the plots shown in Figure 2.3A demonstrating detection 
of concentrations down to 1 nM. All data points were measure in triplicate and displayed 
as mean ± SD.
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2.3.3 Cellular Uptake of Tm3+-DOTA-CAT
We have previously demonstrated that Tm3+-DOTA-CAT is taken up and retained 
by SN56 cells over-expressing Cat-D [19]. Figure 2.4A shows the quantified uptake in 
cells over-expressing Cat-D. We counted the number of cells that demonstrated uptake 
compared with non-transfected cells. In these uptake experiments, 19% ± 2.0% of cells 
exposed to the agent at 5 pM took up Tm3+-DOTA-CAT, and this number increased with 
concentration so that at 100 pM, 78% ± 6.5% of cells took up and retained the agent. In 
contrast, a maximum of 4.7% ± 1.3% of cells not over-expressing Cat-D retained the 
agent over the entire concentration range. This difference between non-transfected and 
transfected SN56 cells is statistically significant at each concentration (p < 0.05).
60
Contrast Agent Concentration (fxM)
B
Time (Hours)
Figure 2.4: (A) Cellular uptake and retention of Tm -DOTA-CAT was observed in a 
concentration dependent manner in cells over-expressing Cat-D-mCherry. Cell counting 
was performed to compare the percentage of transfected SN56 cells taking up Tm3+- 
DOTA-CAT versus non-transfected cells retaining Tm3+-DOTA-CAT at various 
concentrations after 30 minutes of incubation. The asterisk indicates statistical 
significance at each time point (p < 0.05). Error bars represent standard error of the mean. 
(B) Cell counting was performed on the light microscopy images of SN56 cells incubated 
with Tm3+-DOTA-CAT for 2, 4, 6, and 24 hours with trypan blue (n = 3). There were no 
statistically significant differences in cell survival between any of the time points.
2.3.4 SN56 Neuronal Cell Viability Studies
For a preliminary assessment of the toxicity of this compound, we exposed SN56 
cells in culture to 50 pM of Tm3+-DOTA-CAT for 2, 4, 6, and 24 hours and stained them 
with trypan blue to identify dead cells. Figure 2.4B shows that at 2, 4, 6, and 24 hours, 
88% ± 4.1%, 88% ± 3.6%, 86% ± 3.6%, and 90% ± 6.7% of SN56 cells, respectively,
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were viable. Control cells were left in culture medium for 24 hours. There was no 
significant difference between the percentage of cells surviving in control SN56 cells and 
SN56 cells exposed to Tm3+-DOTA-CAT up to 24 hours.
2.3.5 Western Blotting of Cathepsin-D
We examined the levels of cathepsin-D in control-injected and PSl-dE9 mice by 
western blotting. These blots were then quantified and normalized for protein loading 
using the structural protein alpha tubulin as a loading control (Figure 2.55A). In control 
and PSl-dE9 mice, Cat-D was expressed in an intermediate or immature (46 kDa) and 
mature form (33 kDa). Total Cat-D expression was collected from both immature and 
mature forms of Cat-D expression. Mean relative density ± SEM was calculated for each 
of the following groups: 45 day old controls (0.92 ± 0.02), 45 day old PSl-dE9 (0.98 ± 
0.02), 1 year old controls (1.28 ± 0.08), 1 year old PSl-dE9 (1.40 ± 0.11). There were 
significant differences between 45 day old controls and 1 year old controls (t[4.49], p < 
0.01) and between 45 day old PSl-dE9 and 1 year old PSl-dE9 mice (t[3.89], p < 0.05). 
Although there appeared to be slightly more Cat-D in the 1 year old PSl-dE9 mice than 
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Figure 2.5: (A) Representative western blot of the immature and mature forms of
cathepsin-D. All lanes were loaded with 20 pg of protein. The blot was re-probed with 
alpha tubulin as a loading control. (B) Quantification of total cathepsin-D expression 
levels in 45 day old controls and PSl-dE9 mice and 1 year old controls and PSl-dE9 
mice. Band intensities were quantified and normalized for loading using alpha tubulin. 
Data represent mean ± SD from at least 3 individual mice. There were significant 
differences between the expression of 45 day old controls and 1 year old controls, 45 day 
old PSl-dE9 and 1 year old PSl-dE9, and between 45 day old PSl-dE9 and 1 year old 
controls (p < 0.05).
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2.3.6 Contrast Agent Uptake in the Cortical PSl-dE9 and Control Mouse Brain
Figure 2.6 illustrates contrast agent uptake and retention within the cortex 
immediately dorsal to the hippocampus of both 1 year old control and 1 year old PSl-dE9 
mice at 30 minutes post-injection. There was substantial Cat-D staining in both controls 
and PS 1 -dE9 sections and there was no clear difference between these two groups. Red 
blood cells (RBCs) within blood vessels were autofluorescent in both the green and red 
channels and appeared very bright in these images. The contrast agent was able to 
penetrate the blood brain barrier to transverse into the neuropil as well as into cells 
containing Cat-D.
Tm^-DOTA-CAT Cathepsm-D DAPI Overlay
Non-lnjected Control
Control Injected 30 Minutes
PS1-dE9 Injected 30 Minutes
Figure 2.6: Representative confocal microscopy images of the cerebral cortex in 1 year 
old control and 1 year old transgenic PSl-dE9 mice. The first column illustrates the 
amount of fluorescent signal coming from the green channel (autofluorescence and Tm - 
DOTA-CAT). The second column of images displays the cathepsin-D staining in red. 
DAPI nuclear staining is shown in blue and the overlay of all channels in the last column.
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Each representative confocal image from the cortex was acquired to cover an area 
of 101,250 pm from two sections, performed in triplicate in three control and three PS1- 
dE9 mice at each time point (Figure 2.7A). The mean pixel intensity of the green channel 
was determined for each image using ImageJ software and these were averaged for all of 
the images at each time point (Figure 2.7B). Non-injected mice had the lowest mean 
pixel intensity value 70 ± 0.3 fluorescence units. These non-injected fluorescence values 
were subtracted from the fluorescence units obtained for control and PSl-dE9 injected 
mice at each time point. Control mice exhibited substantial green signal at 30 minutes, 
785 ± 88 fluorescence units which declined over time to 220.3 ± 68 fluorescence units 
and eventually to 2.7 ± 2.7 fluorescence units at 120 minutes (Figure 2.7B). In contrast, 
PSl-dE9 mice demonstrated increased green signal from 30 minutes at 295 ± 11 
fluorescence units which rose to 410 ± 69 fluorescence units at 60 minutes before 
dropping to 89 ± 14 fluorescence units at 120 minutes. A two-tailed paired t-test was 
conducted to compare the mean fluorescence levels across images in control-injected, and 
PSl-dE9 injected mice at each time point. There was a significant difference between the 
mean fluorescence of control and PSl-dE9 mice at 30 minutes (p < 0.05) and 120 minutes
(p < 0.05).
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Figure 2.7: Quantitative uptake and retention of contrast agent in control and PSl-dE9 
cortex of the brain. (A) Normal and PSl-dE9 mice received IV injections of contrast 
agent and were sacrificed at the indicated time point. Coronal sections were taken from 
each brain and representative images showing contrast agent (green) in cortex directly 
dorsal to the hippocampus. (B) Mean pixel intensity (± SEM) of the green channel was 
measured across whole images. Control injected mice exhibited the greatest amount of 
uptake and retention at 30 minutes and returned to non-injected levels of fluorescence by 
120 minutes. PSl-dE9 mice showed a slower uptake of contrast agent, peaking at 60 
minutes and demonstrated a longer period of retention of agent by 120 minutes. The 
asterisks represent a statistical significance of p < 0.05.
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2.3.7 Contrast Agent Uptake in PSl-dE9 and Control CA1 and CA3 Hippocampus
Since the hippocampus is affected early in human AD, we examined the uptake 
and retention of our agent in the CA1 and CA3 regions of the hippocampus of non- 
injected, control, and PSl-dE9 injected mice. This analysis was performed using at least 
three images covering 101,250 pm from at least two sections performed in triplicate 
acquired in the CA1 and CA3 regions of control and PSl-dE9 mice at each time point. 
Non-injected mice had a mean fluorescence level of 927 ± 26 fluorescence units (CA 1) 
and 902 ± 23 fluorescence units (CA 3) (data not shown). These non-injected 
fluorescence values were subtracted from the fluorescence units obtained for control and 
PSl-dE9 injected mice at each time point. Figure 2.8 demonstrates that all injected mice 
exhibited greater fluorescence levels in the CA1 and CA3 regions than in non-injected 
mice. In the CA1 region of the hippocampus, control-injected mice had a mean 
fluorescence level of 197 ± 47 at 30 minutes, 163 ± 39 at 60 minutes, and 75 ± 17 
fluorescence units at 120 minutes. PSl-dE9 injected mice had a mean fluorescence level 
of 68 ± 20 at 30 minutes, 154 ± 28 at 60 minutes, and 122 ± 26 fluorescence units at 120 
minutes. The control-injected mice displayed the greatest amount of fluorescence at the 
30 minute time point and gradually declined over time. In contrast PSl-dE9 injected 
mice showed an increasing amount of fluorescence from 30 minutes to 60 minutes and 
then an eventual decline at 120 minutes. Between groups, control-injected mice had 
greater tissue fluorescence than PSl-dE9 injected mice at 30 minutes (p < 0.05) and a 
trend towards higher fluorescence at 120 minutes. Within groups, the control mice had 
greater fluorescence at 30 minutes compared to 60 minutes and 120 minutes, and greater 
fluorescence at 60 minutes compared to 120 minutes (p < 0.05). The PSl-dE9 mice had 
greater fluorescence at 60 minutes compared to 30 minutes (p < 0.05).
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In the CA3 region, both control and in PSl-dE9 injected mice displayed a similar 
pattern of contrast agent uptake to that observed in the CA1 hippocampus region. Control 
injected mice had a mean fluorescence level of 215 ± 25 at 30 minutes, 202 ± 36 at 60 
minutes, and 106 ± 23 fluorescence units 120 minutes. PSl-dE9 injected mice had a 
mean fluorescence level of 103 ± 30 at 30 minutes, 152 ± 32 at 60 minutes, 140 ±51 
fluorescence units at 120 minutes. Between groups, control-injected mice had greater 
fluorescence than PSl-dE9 injected mice at 30 minutes (p < 0.05). Within groups, 
control had greater fluorescence at 30 minutes and 60 minutes compared to 120 minutes 
(p < 0.05).
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Figure 2.8: CA1 (A) and CA3 (B) hippocampal mean pixel intensities in control and 
PSl-dE9 at various time points. Control injected mice had the greatest amount of uptake 
and retention at 30 minutes and then decreasing fluorescence over time in both regions of 
the hippocampus. PSl-dE9 injected mice exhibited a delayed uptake with peak 
fluorescence levels at 60 minutes with washout occurring at 120 minutes. Similar uptake 
patterns were observed in both the CA1 and CA3 regions of the hippocampus as 
compared to that observed in the cortex. There was a significant difference in the uptake 
and retention of Tm3+-DOTA-CAT between control-injected and PSl-dE9-injected mice 
in the CA1 and CA3 regions of the hippocampus at 30 minutes. The asterisks represent a 
statistical significance of p < 0.05.
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In the current study, a strategy is presented to diagnose AD that may be useful at 
the earliest stages of the disease. This strategy is based on the observation that the 
upregulation of lysosomes and lysosome related organelles and enzymes are a very early 
event in AD. The goal of this study was to demonstrate the tissue uptake and retention of 
a novel type of MRI contrast agent based on the activity of the lysosomal enzyme 
cathepsin-D. Here we present two variations of the contrast agent and demonstrate that 
these agents can be detected experimentally using both MRI and optical imaging 
techniques. Specifically, we demonstrated detection of Gd -DOTA-CAT by MRI in a 
concentration range from 50-500 pM, where it exhibited greater sensitivity than clinically 
used Gd3+-DTPA at 9.4 Tesla. The experimentally observed relaxivity for Gd3+-DTPA 
was also verified in similar in-vitro studies [32, 33], Previously, Tm3+-DOTA-CAT was 
also detected by MRI using OPARACHEE contrast at 0.5-4 mM concentrations at 9.4 
Tesla [19]. In the current study, in-vitro cellular uptake studies demonstrated that Tm3+- 
DOTA-CAT was taken up and retained by SN56 neuronal cells over-expressing Cat-D in 
a concentration dependant manner with minimal toxicity. We also studied the time 
course of uptake and retention in aged normal and AD-mice within the cortex, CA1 and 
CA3 regions. The time course of uptake and retention of the fluorescent agent was 
clearly different in the AD and control mice and would allow the differentiation of these 
two groups of mice.
Unfortunately the mouse line we selected for the study did not express elevated 
levels of Cat-D compared to control mice. This result may have occurred because the 
wrong ages were chosen to study these mice; Cat-D levels did rise with age in the control
2.4 Discussion
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and AD mice strains, and it is likely that Cat-D would rise in the AD mice before the 
control mice. Therefore, determining the time course for increased Cat-D expression in 
this mouse line will be completed in future work. Another possibility is that if Cat-D 
were bound up in insoluble amyloid plaques, it might have been underestimated in 
western blots or immunostaining, as it normally requires harsh organic solvents to recover 
insoluble material from amyloid plaques. Finally, we note that there is considerable 
strain to strain variation in pathology in AD mice, and these mice may simply not over­
express high levels of Cat-D and future studies will assess other transgenic mouse lines 
have greater over-expression.
It is not immediately clear why the newly synthesized Cat-D-targeted agent 
presented in this work was able to distinguish the AD and control mice despite these mice 
having similar levels of Cat-D. One possible explanation is that the Cat-D in AD mice 
might be distributed differently than that found in control mice. For example, Cat-D may 
be present more in the extracellular space allowing easier access to the agent. Another 
possibility is that there may be an alteration in the rate of transit of this agent across the 
blood brain barrier in AD mice. Future studies will need to address the importance of the 
Cat-D interaction and cleavage in producing these signal differences.
Currently, the leading candidates for diagnostic use in AD are amyloid binding 
compounds such as the Pittsburgh B (PIB) [34] compound and florbetapir [35], These 
compounds bind to [3-amyloid aggregates in the brain and are detected using Positron 
Emission Tomography (PET). Whether PIB or florbetapir-PET imaging constitute as 
good biomarkers for AD also depends on whether P-amyloid burden in the brain is indeed 
the earliest or best pathology on which to focus. Currently, the diagnostic use of these 
agents is limited by substantial overlap in signals between controls, subjects with mild
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AD/Mild Cognitive impairment, and AD [36-39]. In other words some AD patients do 
not take up these compounds, and many normal controls have high uptake. Sorting out the 
importance of these findings will require extended follow up of affected individuals. In 
addition, there is significant evidence that the insoluble fibrillar amyloid in plaques that 
amyloid agents bind might not be the most relevant form of amyloid. In fact the earliest 
cognitive changes correlate with soluble diffusible amyloid species [40-42], By focusing 
on changes in lysosomal biochemistry, it is possible that our agent might identify 
metabolically abnormal cells and tissues before there is substantial amyloid accumulation 
or deposition.
2.5 Conclusions
Here we present our first animal data in development of an MRI contrast agent to 
quantify enzymatic activity in an intact animal and its application to AD. Despite our 
selection of an AD mouse model that does not have a large change in Cat-D expression 
from controls at 1 year of age, our data demonstrates a clear difference in the uptake and 
retention pattern of Tm3+-DOTA-CAT over time. Therefore, this agent shows significant 
potential as a molecular imaging probe for AD. Future studies will extend our 
understanding of the uptake and retention characteristics of this agent across different AD 
mouse strains and across the lifespan of the animals, with the goal being to identify the 
earliest time point in which we can distinguish control from AD. Future studies will also 
examine the potential for this agent to identify specific cancers with known elevation of
Cat-D.
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Chapter 3: Contributions and Future Work
3.1 Contributions
The major contribution of this thesis was the characterization of the cellular and 
in-vivo uptake and retention of a novel MRI contrast agent targeted to cathepsin-D. In the 
work described within our first publication, we demonstrated several key features: 1) the 
MRI tag was successfully detected using OPARACHEE contrast, 2) the fluorescent probe 
was observed under confocal microscopy, 3) cathepsin-D was able to recognize and 
correctly cleave the contrast agent, and 4) the cell-penetrating peptide portion of the 
compound enabled increased cellular uptake into neurons.
The work presented in Chapter 2 which forms the main body of this thesis builds 
upon our previous contrast agent characterization and provides further verification of 
uptake and retention in an in-vivo animal model. More specifically: 1) Ti relaxivity was 
measured using version of the agent that contained gadolinium, 2) fluorescence sensitivity 
was measured (in nanomolar concentrations), 3) cellular uptake and rentention into 
neurons was quantified, 4) cathepsin-D protein expression was assessed in a transgenic 
model of AD, 5) and the cortical and hippocampal uptake and retention of the contrast 
agent was examined within the brain in transgenic AD mice and control mice. The 
cathepsin-D targeted agent studied continues to show promise as a novel means of 
visualizing early pathological changes associated with Alzheimer’s disease.
This final chapter will describe the limitations, preliminary results, and future 
directions for continued development of these targeted MRI contrast agents.
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3.2 Mouse Models with Increased Cathepsin-D Expression
An enhanced understanding of the increased expression of the lysosomal protein 
Cat-D will be important in determining future studies of contrast agent uptake and 
retention. For instance, in our previous study we compared Cat-D expression in one year 
old transgenic mice to control mice. However, greater differences in Cat-D expression 
may have been present between these groups at earlier time points (Figure 3.1). 
Therefore, it would be beneficial to determine the time point that maximizes differences 
in Cat-D expression between the transgenic and control mice. For example, if one were 
to check the Cat-D levels for these mice at three or six months, there may be a larger 
variation in Cat-D expression between the two groups. A larger difference in Cat-D 
expression between the models would allow for a better understanding of the specific 
uptake and retention of contrast agent. An expanded search for an optimal mouse model 
would evaluate several different strains of transgenic Alzheimer’s mice and compare their 
Cat-D expression at various time points. The goal of these studies would be to 
characterize the increased and/or rate of change of Cat-D expression of transgenic AD 
mice. As a result, model specific age-groups could be chosen to compare contrast agent 
uptake and retention.
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Figure 3.1: Hypothetical representation of Cat-D expression of transgenic and control 
mice at various ages. Notice that if the Cat-D expression difference is large, for example 
indicated by the dotted blue line at 6 months, this time represents the optimal point of 
evaluation of contrast agent uptake in-vivo. It is possible that after one year or prior to 
three months of age, that both transgenic and control mice display the same level of Cat- 
D expression as our western blots have shown.
3.3 In-Vivo MRI Contrast Agent Uptake
At the current time, the Tnr-DOTA-CAT version of contrast agent has not been 
detected within in-vivo brain tissues by PARACEST MRI. This limitation is due to the 
low sensitivity of PARACEST detection due to the competing effects from endogenous 
macromolecules. Two solutions can be proposed to increase the detectability of the 
contrast agent in-vivo. First, a larger concentration of Tm -DOTA-CAT could be 
administered in order to achieve greater detection sensitivity of the agent in-vivo. 
However, care must be taken when the concentration used is greater than the 
recommended dose for in-vivo animal studies. Secondly, in-vivo imaging studies could 
be performed using the gadolinium metalated version of the contrast agent (lanthanide 
metal switch from thulium to gadolinium). The MRI sensitivity of Gd3t-DOTA-CAT
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was shown in chapter two to be greater than clinically used Gd3+-DTPA (Magnevist®) at 
9.4 Tesla. In a preliminary study, a single Alzheimer’s Precursor Protein (APP) mouse 
obtained as a gift from Richard Rozmahel was injected with 2 mM Gd3+-DOTA-CAT 
during imaging on a 9.4T MRI scanner [1], These transgenic APP mice exhibit many of 
the histopathological changes of AD in humans [2], Figure 3.2 illustrates a coronal slice 
of the mouse brain with highlighted regions of interest post-injection. Non-cerebral 
vasculature, cerebral vasculature, and whole brain regions were highlighted in white, 
purple, and red respectively. Seven minutes of baseline scanning was performed prior to 
injection of Gd3+-DOTA-CAT.
Figure 3.2: In-vivo MRI detection of Gd3+-DOTA-CAT using a Ti-weighted spin-echo 
pulse sequence. Three regions of interest were examined: whole brain (Region 1; outlined 
in red), non-cerebral vasculature (Region 2; outlined in purple), and cerebral vasculature 
(Region 3; outlined in white).
Signal intensity was measured over time pre-, during, and post-injection in these 
regions of interest (Figure 3.3). The non-cerebral blood vessel signal (Region 2) intensity 
increased by a maximum of 45%, the cerebral blood vessel signal (Region 3) increased by
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14% and the whole brain signal (Region 1) changed by approximately 3% post-injection. 
Injection of agent occurred at the seven minute mark. Examining the whole brain signal, 
it is difficult to discern the difference in signal from small blood vessels compared to 
contrast agent that has been taken up into the brain tissues. Histological sections would 
confirm the presence of contrast agent within the brain tissues in future follow up studies. 
This mouse had a decline in its vital signs at 16 minutes post-injection.
? t 1 1 t—---------r----------t   ......f................r—-—nr
Time course (min)
Figure 3.3: Quantitative uptake of Gd3+-DOTA-CAT in the APP mouse brain. Signal 
intensity as a function of time following normalization to 100 at baseline.
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3.4 Toxicology and Safety of Contrast Agents
Pharmacokinetics of each new agent tested in-vivo must be evaluated to determine 
their metabolism and clearance from the body. Along with the previous injection study 
from Chapter 2, the liver and kidneys were extracted to examine contrast agent uptake at 
various time points post-injection (30, 60, 120 minutes). These tissues will be examined 
ex-vivo or post-mortem for uptake of contrast agent either using MRI or through 
histology. This information would be highly valuable in determining the half-life of the 
agent within the body and would be critical to move this contrast agent from a pre-clinical 
to a clinical phase. Further characterization of the safety parameters would also be of 
significant importance.
3.5 Limitations to Contrast Agent Design
Both the thulium and gadolinium versions of contrast agent described in this thesis 
are of a preliminary configuration that may be modified in future studies to maximize 
their in-vivo potential.
One such molecular modification to both contrast agents would be PEGylation to 
increase the lifetime of the contrast agents within the blood [3], In addition to longer 
post-injection lifespan, PEGylation reduces metabolic degradation, and is 
immunologically inert [4], PEGylation is the process of adding polyethelene glycol 
polymer chains to a molecule. This modification is typically performed on compounds 
such as contrast agents or drugs. PEGylation has been approved by the Food and Drug 
Administration (FDA) and is currently used in a number of drugs on the market today [5],
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A second modification to the contrast agent could involve adding the capability 
for fluorescence resonance energy transfer (FRET) to more directly measure enzymatic 
activity in-vivo. FRET imaging would allow the contrast agent to fluorescence only when 
it is less than 10 nm from the protein of interest [6, 7]. This alteration would ultimately 
enable true recognition of the interaction between Cat-D and contrast agent at the 
molecular level. Lastly, cell viability studies could be extended to include assays for a 
more sensitive measure of cellular death. However, a recent paper on the toxicity of a
O I
similar contrast agent Eu -DOTA-(Gly)4 demonstrated that DOTA-caged MR contrast 
agents were even less toxic than their gadolinium counterparts [8],
3.6 Limitations to Uptake Studies
In order to provide proper controls for each new contrast agent, several modified 
forms of the agent must be created to examine their uptake and retention. Two of the four 
major components of the contrast agent that could be altered are the cell-penetrating 
peptide (CPP) and the Cat-D recognition sequences. By evaluating these regions, the true 
specificity and retention of contrast agents would be determined with the appropriate 
controls. For instance, the cell-penetrating peptide or TAT region of the compound 
should be removed to evaluate the enhanced uptake of compound in comparison to the 
original agent. The CPP may be cleaved or removed in its entirety to model its efficacy 
(Figure 3.4). These studies may be performed both in-vitro and in-vivo to evaluate uptake 
of contrast agent. The second region to be modified would be the Cat-D recognition site. 
The amino acid sequence should be scrambled so that the Cat-D enzyme would be unable 
to cleave at this site. The effect of this change would be to evaluate how well Cat-D
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recognizes and cleaves the compound but also to evaluate the amount of time the agent is 
retained within biological tissues.
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Figure 3.4: Design of control contrast agents to evaluate uptake efficiency of the targeted 
Cat-D contrast agent. By modifying the CPP portion of the compound, the difference in 
uptake within biological samples may be evaluated. Scrambling the Cat-D recognition 
sequence may provide additional information on the targeting and retention of contrast 
agent within biological tissues.
3.7 Future of Contrast Agents in Imaging Alzheimer’s Disease
Novel biomarkers will continue to be developed in order to diagnose, monitor or 
predict pre-symptomatic AD. The most important feature of novel biomarkers will be 
their ability to specifically identify a particular disease mechanism. As our understanding 
of Alzheimer’s disease pathology increases, the type of biomarkers being developed for 
certain targets may change. In addition, one biomarker may not necessarily provide 
enough evidence to diagnose an individual but rather several biomarkers may be required 
indicating a progression of AD.
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